BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Fingolimod Hydrochloride

A sphingosine-derivative and IMMUNOSUPPRESSIVE AGENT that blocks the migration and homing of LYMPHOCYTES to the CENTRAL NERVOUS SYSTEM through its action on SPHINGOSINE 1-PHOSPHATE RECEPTORS. It is used in the treatment of MULTIPLE SCLEROSIS.

56+ PubMed studies analyzed · 1 RCTs · Evidence Score: 45.7

Research Domains

Fingolimod Hydrochloride has been studied across 15 research domains including 🛡️ Immunity, 😴 Sleep, 🔥 Metabolic, ❤️ Cardiovascular, 🔬 Oncology. The primary research focus is 🛡️ Immunity with 32% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Fingolimod Hydrochloride, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

Celecoxib
2 shared targets
Niclosamide
2 shared targets
mylabris
2 shared targets
dendrobium
2 shared targets
anemarrhena
2 shared targets
curculigo
2 shared targets
gentiana
2 shared targets
platycodon
2 shared targets
Foeniculum
2 shared targets
allium
2 shared targets
Loading evidence profile...

This evidence profile for Fingolimod Hydrochloride is generated deterministically from 56 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.